Advertisement
Australia markets closed
  • ALL ORDS

    8,491.50
    -7.20 (-0.08%)
     
  • ASX 200

    8,214.50
    -8.50 (-0.10%)
     
  • AUD/USD

    0.6753
    +0.0010 (+0.14%)
     
  • OIL

    75.49
    -0.36 (-0.47%)
     
  • GOLD

    2,674.20
    +34.90 (+1.32%)
     
  • Bitcoin AUD

    92,681.88
    +3,702.42 (+4.16%)
     
  • XRP AUD

    0.80
    +0.02 (+2.42%)
     
  • AUD/EUR

    0.6170
    +0.0011 (+0.18%)
     
  • AUD/NZD

    1.1041
    -0.0013 (-0.12%)
     
  • NZX 50

    12,845.64
    +91.06 (+0.71%)
     
  • NASDAQ

    20,271.97
    +30.21 (+0.15%)
     
  • FTSE

    8,253.65
    +15.92 (+0.19%)
     
  • Dow Jones

    42,863.86
    +409.74 (+0.97%)
     
  • DAX

    19,373.83
    +162.93 (+0.85%)
     
  • Hang Seng

    21,251.98
    +614.74 (+2.98%)
     
  • NIKKEI 225

    39,605.80
    +224.91 (+0.57%)
     

Australian Clinical Labs Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Australian Clinical Labs (ASX:ACL) Full Year 2024 Results

Key Financial Results

  • Revenue: AU$697.5m (flat on FY 2023).

  • Net income: AU$23.9m (down 33% from FY 2023).

  • Profit margin: 3.4% (down from 5.2% in FY 2023).

  • EPS: AU$0.12 (down from AU$0.18 in FY 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Australian Clinical Labs Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 13%.

Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Healthcare industry in Australia.

Performance of the Australian Healthcare industry.

The company's shares are up 3.9% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Australian Clinical Labs that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.